Could our own immune system be cancer’s undoing? New therapies that harness the immune system are beginning to make their way to the clinic, with many more in the pipeline. In our Eureka video blog, Aidan Synnott, Director of Global Business Operations, Discovery Research Services at Charles River Laboratories, chats with Wendy Metz, Marketing Manager, Global Discovery Research Services, about how immunotherapies are transforming a therapeutic arsenal traditionally dominated by chemotherapeutic drugs. Some of these immunotherapies will be a focus of Charles River’s upcoming symposium Oct. 14 at Harvard Medical School that will feature Craig B. Thompson, Chief Executive Officer of Memorial Sloan Kettering Cancer Center, one of the pioneers in cancer immunotherapy. The New Approaches to Cancer Drug Discovery symposia also included events earlier this year in San Francisco and London.